Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humanized CD19 CAR-T for B-cell Malignancies
NCT02782351Phase 2Unknown
- Start
- May 2016
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B-cell hematologic malignancy and chronic lymphocytic leukemia (CLL). Primary endpoint: CAR-T cells persistence in peripheral blood at 12 months. Status: unknown.
02
Conditions
B-cell hematologic malignancychronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02782351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782351.